BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 03/30/23

BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update PR Newswire Biologics License Application for NurOwn® for the treatment of ALS to be discussed in an upcoming FDA Advisory Committee Meeting Conference call and...

2023-03-29 12:56:48 ET Gainers: Bird Global ( BRDS ) +44% . Toro Corp ( TORO ) +38% . RenovoRx ( RNXT ) +29% . Arcturus Therapeutics ARCT +26% . Tempest Therapeutics ( TPST ) +26% . Brainstorm Cell Therapeutics ( BCLI ) ...

2023-03-29 10:28:48 ET Major earning expected before the bell on Thursday include: EVgo ( EVGO ) Imunon ( IMNN ) Li-Cycle Holdings ( LICY ) Nano Dimension ( NNDM ) PetroChina (PTR) For further details see: Notable earnings before Thursday's open

2023-03-27 06:48:42 ET BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) announced Monday that the FDA is expected to hold an advisory committee meeting to discuss the marketing application for its lead asset NurOwn targeted at rare neurodegenerative disorder amyotrophic lateral s...

BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS PR Newswire Conference call and webcast at 8:00 a.m. ET NEW YORK , March 27, 2023 /PRNewswire/ --&#...

BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , March 21, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neuro...

BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study PR Newswire Serum and cerebrospinal fluid samples from the Phase 3 study of NurOwn ® in ALS to be donated to th...

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023 PR Newswire NEW YORK , Jan. 5, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases,...

Stem cell therapeutics developer BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) has promoted Stacy Lindborg to the role of co-CEO. Lindborg, who joined BrainStorm in 2020, will work alongside Chaim Lebovits, who is retaining his position as president and CEO. In addition, Ralph...

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer PR Newswire NEW YORK , Jan. 4, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for...